المؤلفون: Gudewicz I, Hajtuch J, Zaucha R

المصدر: Open Access Journal of Clinical Trials, Vol Volume 16, Pp 1-9 (2024)

مصطلحات موضوعية: study coordinator, clinical research, clinical trials, management, patients., Medicine

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/center-with-or-without-a-coordinator-the-coordinator-as-an-integral-pa-peer-reviewed-fulltext-article-OAJCTTest; https://doaj.org/toc/1179-1519Test

الوصول الحر: https://doaj.org/article/02ec3412b3c6453587065c3f86f9ea3eTest

المؤلفون: Yau, T., Park, J. W., Finn, R. S., Cheng, A. L., Mathurin, Philippe, Edeline, Julien, Kudo, M., Harding, J. J., Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, L., Schott, E., Choo, S. P., Kelley, R. K., Sieghart, W., Assenat, Eric, Zaucha, R., Furuse, J., Abou-Alfa, G. K., El-Khoueiry, A. B., Melero, I., Begic, D., Chen, G., Neely, J., Wisniewski, T., Tschaika, M., Sangro, B.

المساهمون: Université de Lille, Inserm, CHU Lille, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, CRLCC Eugène Marquis CRLCC, Hôpital de la Croix-Rousse CHU - HCL, CHU Pitié-Salpêtrière AP-HP, Hôpital Saint Eloi CHRU Montpellier

العلاقة: Lancet Oncol; http://hdl.handle.net/20.500.12210/100999Test

الإتاحة: https://doi.org/20.500.12210/100999Test
https://hdl.handle.net/20.500.12210/100999Test

المؤلفون: Musial C., Zaucha R., Kuban-Jankowska A., Konieczna L., Belka M., Gammazza A. M., Baczek T., Cappello F., Wozniak M., Gorska-Ponikowska M.

المساهمون: Musial C., Zaucha R., Kuban-Jankowska A., Konieczna L., Belka M., Gammazza A.M., Baczek T., Cappello F., Wozniak M., Gorska-Ponikowska M.

مصطلحات موضوعية: estrogen, lung cancer, sex hormone, lung adenocarcinoma, estrogen receptor, 17- estradiol, p53, A549, non-small cell lung cancer, NSCLC

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33466597; info:eu-repo/semantics/altIdentifier/wos/WOS:000611276900001; volume:18; issue:2; firstpage:1; lastpage:15; numberofpages:15; journal:INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH; http://hdl.handle.net/10447/528324Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85099399657; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828659Test/

الإتاحة: https://doi.org/10.3390/ijerph18020648Test
http://hdl.handle.net/10447/528324Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828659Test/

المؤلفون: Trojan J., Mollon P., Daniele B., Marteau F., Martin L., Li Y., Xu Q., Piscaglia F., Zaucha R., Sarker D., Lim H. Y., Venerito M.

المساهمون: Trojan J., Mollon P., Daniele B., Marteau F., Martin L., Li Y., Xu Q., Piscaglia F., Zaucha R., Sarker D., Lim H.Y., Venerito M.

مصطلحات موضوعية: Alpha-fetoprotein (AFP), Cabozantinib, Hepatocellular carcinoma (HCC), Indirect treatment comparison (ITC), Matching-adjusted indirect comparison (MAIC), Monoclonal antibody (mAb), Ramucirumab, second-line treatment / 2L treatment, Tyrosine kinase inhibitor (TKI), Vascular endothelial growth factor (VEGF)

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33822328; info:eu-repo/semantics/altIdentifier/wos/WOS:000637450100001; volume:38; issue:5; firstpage:2472; lastpage:2490; numberofpages:19; journal:ADVANCES IN THERAPY; https://hdl.handle.net/11585/858948Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85103671407; https://link.springer.com/article/10.1007/s12325-021-01700-2Test

الإتاحة: https://doi.org/10.1007/s12325-021-01700-2Test
https://hdl.handle.net/11585/858948Test

المؤلفون: Oh, D., He, A. R., Qin, S., Chen, L., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Lee, M. A., Kitano, M., Burris, H. A., Bouattour, M., Tanasa, S., Zaucha, R. E., Avallone, A., Cundom, J. E., Rokutanda, N., Zotkiewicz, M., Cohen, G., Valle, Juan W

المساهمون: Division Of Medical Oncology, Department Of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, 110-744 - Seoul/KR

العلاقة: https://dx.doi.org/10.1016/annonc/annonc1123Test; Oh D, He AR, Qin S, Chen L, Okusaka T, Vogel A, et al. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (D GC) in patients (pts) with advanced biliary tract cancer (BTC) (vol 33, pg s1462, 2022). Annals of Oncology. 2023 Jul;34(7):633-. PubMed PMID: WOS:001033922200001.; http://hdl.handle.net/10541/626531Test; Annals of Oncology

الإتاحة: https://doi.org/10.1016/annonc/annonc1123Test
http://hdl.handle.net/10541/626531Test

المؤلفون: Oh, DY, He, AR, Qin, SK, Chen, LT, Okusaka, T, Vogel, A, Kim, JW, Suksombooncharoen, T, Lee, MA, Kitano, M, Burris, H, Bouattour, M, Tanasanvimon, S, McNamara, Mairead G, Zaucha, R, Avallone, A, Tan, BJM, Cundom, J, Lee, CK, Takahashi, H, Ikeda, M, Chen, JS, Wang, JL, Makowsky, M, Rokutanda, N, Zotkiewicz, M, Kurland, JF, Cohen, G, Valle, Juan W

المساهمون: Division of Cancer Sciences, The University of Manchester/The Christie NHS Foundation Trust, Manchester, UK

العلاقة: https://dx.doi.org/10.2217/fon-2023-0468Test; Oh DY, He AR, Qin SK, Chen LT, Okusaka T, Vogel A, et al. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer. FUTURE ONCOLOGY. 2023 2023 SEP 25. PubMed PMID: WOS:001077451100001. English.; http://hdl.handle.net/10541/626755Test; Future Oncology

الإتاحة: https://doi.org/10.2217/fon-2023-0468Test
http://hdl.handle.net/10541/626755Test

المؤلفون: Oh, D. Y., He, A. R., Qin, S., Chen, L. T., Okusaka, T., Vogel, A., Kim, J. W., Lee, T., Lee, M. A., Kitano, M., Burris, H. A., Bouattour, M., Tanasanvimon, S., Zaucha, R. E., Avallone, A., Cundom, J. E., Rokutanda, N., Zotkiewicz, M., Cohen, G., Valle, Juan W

المساهمون: Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China

العلاقة: https://dx.doi.org/10.1016/j.annonc.2022.10.113Test; Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC). Annals of Oncology. 2022 Nov;38(9):S1462-S3. PubMed PMID: WOS:000897943700080.; http://hdl.handle.net/10541/626136Test; Annals of Oncology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.10.113Test
http://hdl.handle.net/10541/626136Test

المؤلفون: Oh, D. Y., He, A. R., Qin, S., Chen, L. T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Lee, M. A., Kitano, M., Burris, H. A., Bouattour, M., Tanasanvimon, S., Zaucha, R., Avallone, A., Cundom, J., Rokutanda, N., Xiong, J., Cohen, G., Valle, Juan W

المساهمون: Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

العلاقة: https://dx.doi.org/10.1200/JCO.2022.40.4_suppl.378Test; Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Vol. 40, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 378–378.; http://hdl.handle.net/10541/625226Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2022.40.4_suppl.378Test
http://hdl.handle.net/10541/625226Test

المؤلفون: Zaucha, J.M., Małkowski, B., Chauvie, S., Subocz, E., Tajer, J., Kulikowski, W., Fijołek-Warszewska, A., Biggi, A., Fallanca, F., Kobylecka, M., Dziuk, M., Woszczyk, D., Rybka, J., Kroll-Balcerzak, R., Bergesio, F., Romanowicz, A., Chamier-Ciemińska, A., Kurczab, P., Giza, A., Leśniewski-Kmak, K., Zaucha, R., Świetlik, D., Wróbel, T., Knopińska-Posłuszny, W., Walewski, J., Gallamini, A.

المصدر: Annals of Oncology ; volume 28, issue 12, page 3051-3057 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1093/annonc/mdx524Test
https://api.elsevier.com/content/article/PII:S0923753419353888?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753419353888?httpAccept=text/plainTest
http://academic.oup.com/annonc/article-pdf/28/12/3051/22295515/mdx524.pdfTest

المؤلفون: Yau, T. (Thomas), Park, J.W. (Joong-Won), Finn, R.S. (Richard S.), Cheng, A.L. (Ann-Lii), Mathurin, P. (Philippe), Edeline, J. (Julien), Kudo, M. (Masatoshi), Harding, J.J. (James J.), Merle, P. (Philippe), Rosmorduc, O. (Olivier), Wyrwicz, L. (Lucjan), Schott, E. (Eckart), Choo, S.P. (Su-Pin), Kate-Kelley, R. (Robin), Sieghart, W. (Wolfgang), Assenat, E. (Eric), Zaucha, R. (Renata), Furuse, J. (Junji), Abou-Alfa, G.K. (Ghassan K.), El-Khoueiry, A. (Anthony), Melero, I. (Ignacio), Begic, D. (Damir), Chen, G. (Gong), Neely, J. (Jaclyn), Wisniewski, T. (Tami), Tschaika, M. (Marina), Sangro, B. (Bruno)

مصطلحات موضوعية: Materias Investigacion::Ciencias de la Salud, Nivolumab, Sorafenib, Hepatocellular carcinoma

وصف الملف: application/pdf

العلاقة: https://hdl.handle.net/10171/68732Test

الإتاحة: https://hdl.handle.net/10171/68732Test